---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-017224"
form_type: "8-K"
ticker: "TOI"
cik: "0001799191"
company_name: "Oncology Institute, Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T06:52:34.262005+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Oncology Institute Q1 revenue $76M (+38% YoY) but net loss $30M, EBITDA loss widens

## Summary
- Revenue of $76M, up 38.1% YoY; gross profit $14M (18.5% margin, down from 22.3%).
- Net loss of $30M ($0.33 diluted loss) vs net income of $19.3M ($0.22 EPS) in Q1 2022.
- Adjusted EBITDA loss of $7.9M vs loss of $5.2M in prior year; cash of $114M.
- Patient visits up 17% YoY; oral drugs dispensed up 34% YoY.
- New value-based contracts in CA and TX; Florida gainshare shows >50% referral capture and >30% cost savings; Q3 guidance reaffirmed.

## SEC filing metadata
- accession: 0001628280-23-017224
- form_type: 8-K
- ticker: TOI
- cik: 0001799191
- company_name: Oncology Institute, Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799191/000162828023017224/0001628280-23-017224-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799191/000162828023017224/toi-20230510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-017224
- JSON: https://secwatch.observer/filing/0001628280-23-017224.json
- Plain text: https://secwatch.observer/filing/0001628280-23-017224.txt

## Key facts
- Earnings Releases
  Oncology Institute, Inc. reported three months ended March 31, 2023 results: revenue $76 million, net income Net loss of $30.0 million, EPS $(0.33). Guidance reaffirmed.
  - Period: three months ended March 31, 2023
  - Revenue: $76 million
  - Net income: Net loss of $30.0 million
  - EPS: $(0.33)
  - Guidance: reaffirmed
  - Result: reported results
  source text: savings • Patient visits up 17% compared to Q1 2022 • Oral drugs dispensed increased 34% compared to Q1 2022 First Quarter 2023 Financial Highlights • Consolidated revenue of $76 million, an increase of 38.1% from $55 million compared to the prior year quarter • Gross profit of $14 million, an increase of 14.4% compared to the prior year quarter, and gross margin
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799191/000162828023017224/0001628280-23-017224-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.